These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35901521)
21. [Advances in the management of inflammatory bowel diseases]. Reenaers C; Louis E Rev Med Liege; 2022 May; 77(5-6):323-329. PubMed ID: 35657190 [TBL] [Abstract][Full Text] [Related]
22. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
23. Are we using and monitoring thiopurines and biologics optimally? Irving PM Dig Dis; 2014; 32(4):410-8. PubMed ID: 24969289 [TBL] [Abstract][Full Text] [Related]
24. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif]. Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976 [TBL] [Abstract][Full Text] [Related]
25. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. Schoepfer A; Vavricka SR; Brüngger B; Blozik E; Bähler C Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):350-357. PubMed ID: 31834046 [TBL] [Abstract][Full Text] [Related]
26. The role of biologics in the treatment of patients with inflammatory bowel disease. Selinger CP; Carbery I; Al-Asiry J Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103 [TBL] [Abstract][Full Text] [Related]
27. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children]. Kolacek S Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292 [TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive therapies for inflammatory bowel disease. Zenlea T; Peppercorn MA World J Gastroenterol; 2014 Mar; 20(12):3146-52. PubMed ID: 24696600 [TBL] [Abstract][Full Text] [Related]
29. [Incidence of inflammatory bowel diseases in the department of Puy-de-Dôme in 1993 and 1994. EPIMICI. Epidémiologie des Maladies Inflammatoires Cryptogenetiques de l'Intestin group]. Flamenbaum M; Zénut M; Aublet-Cuvelier B; Larpent JL; Fabre P; Abergel A; Dapoigny M; Bommelaer G Gastroenterol Clin Biol; 1997; 21(6-7):491-6. PubMed ID: 9295977 [TBL] [Abstract][Full Text] [Related]
30. Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002. Bauer N; Kairey L; Schlee C; Uecker C; Öznur Ö; Langhorst J Scand J Gastroenterol; 2022 Oct; 57(10):1209-1215. PubMed ID: 35722930 [TBL] [Abstract][Full Text] [Related]
38. [Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases]. Buc M Vnitr Lek; 2018; 64(3):280-289. PubMed ID: 29766731 [TBL] [Abstract][Full Text] [Related]
39. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970 [TBL] [Abstract][Full Text] [Related]
40. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Privitera G; Pugliese D; Onali S; Petito V; Scaldaferri F; Gasbarrini A; Danese S; Armuzzi A Autoimmun Rev; 2021 Jun; 20(6):102832. PubMed ID: 33866066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]